Photo from Day One Biopharmaceuticals/LinkedIn
Jul 29, 2024, 07:51
Day One Biopharmaceuticals’ new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib
Day One Biopharmaceuticals shared a post on LinkedIn:
“We are pleased to announce a new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib. This collaboration highlights our shared commitment to bring novel therapeutics to patients worldwide who have limited treatment options. Learn more.”
shared the post by Day One Biopharmaceuticals on LinkedIn, adding:
“Excited to partner with Ipsen to help kids and families with pediatric low grade gliomas worldwide!”
Source: Day One Biopharmaceuticals/LinkedIn and